Role for direct electronic verification of pharmaceutical ingestion in pharmaceutical development

Contemporary Clinical Trials

Volumn 33, Issue 4, 2012, Pages 593-600

  DiCarlo, Lorenzo A ^a  

^a Proteus Biomedical Inc   (United States)

Author keywords

Adherence; Clinical trial monitoring; Clinical trial tool; Data collection; Study design

Indexed keywords

ATENOLOL; BETAXOLOL; EXCIPIENT;

ARTICLE; BIOSENSOR; CLINICAL RESEARCH; COMPARTMENT MODEL; DIAGNOSTIC ACCURACY; DOSE RESPONSE; DRUG EFFECT; DRUG EXPOSURE; DRUG INDUSTRY; DRUG RESPONSE; DRUG USE; ELECTRONIC PRESCRIBING; ELECTRONIC SENSOR; ENCAPSULATION; HUMAN; INGESTION; PATIENT COMPLIANCE; PHARMACOLOGICAL PARAMETERS; SIMULATION; STEADY STATE;

CLINICAL TRIALS AS TOPIC; DATA COLLECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MEDICATION ADHERENCE; MONITORING, PHYSIOLOGIC; RESEARCH DESIGN;

EID: 84861528142     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2012.03.008     Document Type: Article

References (44)

1. Kenna L.A., Sheiner L.B. Estimating treatment effect in the presence of non-compliance measured with error: precision and robustness of data analysis methods. Stat Med 2004, 23:3561-3580.
2. Cross J., Lee H., Westelinck A., Nelson J., Grudzinskas C., Peck C. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999. Pharmacoepidemiol Drug Saf 2002, 11:439-446.
3. Cohen J.S. Dose discrepancies between the Physicians' Desk Reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug events. Arch Intern Med 2001, 161:957-964.
4. Barrett J.S., Labbe L., Pfister M. Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy. Clin Pharmacokinet 2005, 44:591-625.
5. Cramer J.A. Microelectronic systems for monitoring pharmacotherapy. Clin Pharmacokinet 1997, 32:345-356.
6. Kastrissios H., Blaschke T.F. Medication compliance as a feature in drug development. Annu Rev Pharmacol 1997, 37:451-475.
7. Harter J.G., Peck C.C. Chronobiology. Suggestions for integrating it into drug development. Ann N Y Acad Sci 1991, 618:563-571.
8. Cramer J.A., Spilker B. Compliance in medical practice and clinical trials 1991, Raven Press, New York.
9. Metry J.M., Meyer U.A. Drug regimen compliance: issues in clinical trials and patient management 1999, John Wiley, Chichester UK.
10. Burke L.E., Ockene I.S. Compliance in healthcare and research. American Heart Association Monograph Series 2001, Futura Publishing Co, New York NY.
11. International Conference on Harmonization Choice of control group in clinical trials. FDA Docket 99D-3082. Fed Regist 1999, 64:51767-51780.
12. Urquhart J. Demonstrating effectiveness in the post-placebo era. Clin Pharmacol Ther 1999, 70:155-120.
13. Nedelman J.R. On some "disadvantages" of the population approach. AAPS J 2005, 7(2):E374-E382.
14. Girard P., Sheiner L.B., Kastrissios H., Blaschke T.F. Do we need full compliance data for population pharmacokinetic analysis?. J Pharmacokinet Biopharm 1996, 24:265-282.
15. Vrijens B., Goetghebeur E. The impact of compliance in pharmacokinetic studies. Stat Methods Med Res 1999, 8:247-262.
16. Vrijens B., Goetghebeur E. Electronic monitoring of variation in drug intakes can reduce bias and improve precision in pharmacokinetic/pharmacodynamic population studies. Stat Med 2004, 23:531-544.
17. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic for non-antiarrhythmic drugs October 2005.
18. Health Canada Therapeutic products programme guidance document. Drug-drug interactions: studies in vitro and in vivo September 21, 2000.
19. US Department of Health and Human Services, Food and Drug Administration Guidance for industry: in vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling November 1999.
20. European Medicines Agency Guideline on the investigation of drug interactions (draft) April 22, 2010.
21. US Department of Health and Human Services, Food and Drug Administration Guidance for industry: end-of-phase 2A meetings September 2009.
22. Insull W. Statement of the problem and pharmacological and clinical requirements for the ideal marker. Control Clin Trials 1984, 5:459-462.
23. Friedman L.M., Furberg C.D., DeMets D.L. Fundamentals of clinical trials 2010, Springer Verlag, New York. 4th ed.
24. Weiner D. Modeling, simulation, and the critical path. Drug Discov Dev 2006, 9:54.
25. US Department of Health and Human Services, Food and Drug Administration Guidance for industry: exposure-response relationships - study design, data analysis, and regulatory applications April 2003.
26. Cramer J.A., Scheyer R.D., Mattson R.H. Compliance declines between clinic visits. Arch Intern Med 1990, 150:1509-1510.
27. Laine C., Newschaffer C.J., Zhang D., Cosler L., Hauck W.W., Turner B.J. Adherence to antiretroviral therapy by pregnant women infected with human immunodeficiency virus: a pharmacy claims-based analysis. Pharm World Sci 1998, 20:73-77.
28. Vrijens B., Urquhart J. Patient adherence to prescribed antimicrobial drug dosing regimens. J Antimicrob Chemother 2005, 55:616-627.
29. Rode R., Vrijens B., Niemi K., Wikstrom K., Heuser R., Podsadecki T. Differences in treatment compliance between lopinarvir/ritonavir (LPV/r) given once (QD) versus twice (BID) daily do not affect virologic or immunologic outcomes. 45th Interscience conference on antimicrobial agents and chemotherapy. Washington DC, December 16-19 2005, Poster #H-522.
30. Podsadecki T.J., Vrijens B.C., Tousset E.P., Rode R.A., Hanna G.J. "White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin Trials 2008, 9:238-246.
31. Bova C., Fennie K., Knafl G., Dieckhaus K., Watrous E., Williams A. Use of electronic monitoring devices to measure antiretroviral adherence: practical considerations. AIDS Behav 2005, 9:103-110.
32. Wendel C.S., Mohler M.J., Kroesen K., Ampel N.M., Gifford A.L., Coons S.J. Barriers to use of electronic adherence monitoring in an HIV clinic. Ann Pharmacother 2001, 35:1010-1015.
33. Olivieri N.F., Matsui D., Hermann C., Koren G. Compliance assessed by the Medication Event Monitoring System. Arch Dis Child 1991, 66:1399-1402.
34. Young-Xu Y., Chan K.A. Pooling overdispersed binomial data to estimate event rate. BMC Med Res Methodol 2008, 8:58.
35. Wu J.R., Moser D.K., Chung M.L., Lennie T.A. Objectively measured, but not self-reported, medication adherence independently predicts event-free survival in patients with heart failure. J Card Fail 2008, 14:203-210.
36. Stroupe K.T., Teal E.Y., Tu W., Weiner M., Murray M.D. Association of refill adherence and health care use among adults with hypertension in an urban health care system. Pharmacotherapy 2006, 26:779-789.
37. Au-Yeung K., Intondi A., Abdel-Aleem S., Moon G., Belknap R., Reves R., et al. A novel ingestible microsensor system for characterizing adherence to prescribed medication. J Gen Intern Med 2010, 25 (Suppl. 3):S460.
38. Au-Yeung K., Intondi A., Abdel-Aleem S., Moon G., Epstein M., Belknap R., et al. A novel system for electronically confirming adherence to tuberculosis therapy. Presented at the World Healthcare Congress, Washington DC, April 12 2010, http://www.worldcongress.com/events/HR10000/poster-detail.cfm?PosterID=55. Accessed February 3, 2012.
39. United States Food and Drug Administration Alora (estradiol) transdermal new drug application (NDA) number 021310 Accessed. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21310.pdf.
40. United States Package Insert Clonidine-TTS Accessed. http://www.theodora.com/drugs/catapres_tts_boehringer_ingelheim.html.
41. Au-Yeung K., Moon G., Robertson T., DiCarlo L., Epstein M., Weis S., et al. Early clinical experience with networked system for promoting patient self-management. Am J Manag Care 2011, 17:e277-e287.
42. Unpublished data.
43. Johnson B.F., Whelton A. A study design for comparing the effects of missing daily doses of antihypertensive drugs. Am J Ther 1994, 1:260-267.
44. Sambol N.C., Sheiner L.B. Population dose versus response of betaxolol and atenolol: a comparison of potency and variability. Clin Pharmacol Ther 1991, 49:24-31.